Cargando…

Persistence, Adherence, and Switch Rates Among Extended-Release and Immediate-Release Overactive Bladder Medications in a Regional Managed Care Plan

BACKGROUND: Pharmacotherapy constitutes an important adjunct to behavioral therapy for the treatment of overactive bladder (OAB). Tolterodine and oxybutynin are commonly prescribed drugs for OAB treatment that exert their beneficial effect by suppressing bladder muscle contractions. However, high di...

Descripción completa

Detalles Bibliográficos
Autores principales:	D'Souza, Anna O., Smith, Michael J., Miller, Lesley-Ann, Doyle, Joseph, Ariely, Rinat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2008
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438114/ https://www.ncbi.nlm.nih.gov/pubmed/18439051 http://dx.doi.org/10.18553/jmcp.2008.14.3.291

Ejemplares similares

Update on tolterodine extended-release for treatment of overactive bladder
por: Omotosho, Tola, et al.
Publicado: (2010)

The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly
por: Ulahannan, Danny, et al.
Publicado: (2009)

Oxybutynin extended release for the management of overactive bladder: a clinical review
por: Arisco, AM, et al.
Publicado: (2009)

The effect of extended release tolterodine used for overactive bladder treatment on female sexual function
por: Zachariou, Athanasios, et al.
Publicado: (2017)

Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency
por: Lee, Raymond T, et al.
Publicado: (2013)

Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy
por: Zinner, N, et al.
Publicado: (2008)

Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom
por: Aballéa, Samuel, et al.
Publicado: (2014)

Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation
por: Del Bello, Arnaud, et al.
Publicado: (2021)

Reactive Hypoglycemia From Metformin Immediate-Release Monotherapy Resolved by a Switch to Metformin Extended-Release: Conceptualizing Their Concentration-Time Curves
por: Akram, Ayesha
Publicado: (2021)

Health expenditure comparison of extended-release metoprolol succinate and immediate-release metoprolol tartarate
por: Vaidya, Varun, et al.
Publicado: (2012)

Pharmacokinetics of immediate release, extended release, and gastric retentive gabapentin formulations in healthy adults
por: Swearingen, Dennis, et al.
Publicado: (2018)

Single- and multiple-dose pharmacokinetics of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) compared with immediate-release hydrocodone bitartrate/ibuprofen and immediate-release tramadol HCl/acetaminophen
por: Devarakonda, Krishna, et al.
Publicado: (2015)

Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence
por: Muduma, Gorden, et al.
Publicado: (2014)

Drugs for the overactive bladder: are there differences in persistence and compliance?
por: Andersson, Karl-Erik
Publicado: (2017)

Pharmacological and clinical evidence of nevirapine immediate- and extended-release formulations
por: Ena, Javier, et al.
Publicado: (2012)

Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States
por: Iwanicki, Janetta L., et al.
Publicado: (2016)

Comparison of single-dose and multiple-dose pharmacokinetics between two formulations of hydrocodone bitartrate/acetaminophen: immediate-release versus biphasic immediate-release/extended release
por: Devarakonda, Krishna, et al.
Publicado: (2015)

Clinical evaluation of switching from immediate‐release to prolonged‐release lithium in bipolar patients, poorly tolerant to lithium immediate‐release treatment: A randomized clinical trial
por: Pelacchi, Federica, et al.
Publicado: (2022)

Update on the management of overactive bladder: patient considerations and adherence
por: Gomelsky, Alex, et al.
Publicado: (2010)

Long-term adherence to clinical therapy of overactive bladder
por: Drake, Marcus John
Publicado: (2017)

Overactive bladder: strategies to ensure treatment compliance and adherence
por: Dhaliwal, Prabhpreet, et al.
Publicado: (2016)

The Difference in Pharmacokinetics and Pharmacodynamics between Extended-Release Fluvastatin and Immediate-Release Fluvastatin in Healthy Chinese Subjects
por: Xu, H. R., et al.
Publicado: (2012)

Patterns of Immediate-Release and Extended-Release Opioid Analgesic Use in the Management of Chronic Pain, 2003-2014
por: Hwang, Catherine S., et al.
Publicado: (2018)

A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
por: Nazir, Jameel, et al.
Publicado: (2018)

Persistence and compliance with medication management in the treatment of overactive bladder
por: Kim, Tae Heon, et al.
Publicado: (2016)

Comparative effects of immediate‐release and extended‐release aspirin on basal and bradykinin‐stimulated excretion of thromboxane and prostacyclin metabolites
por: Gamboa, Jorge L., et al.
Publicado: (2016)

Extended‐Release Once‐Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate‐Release Tofacitinib and Impact of Food
por: Lamba, Manisha, et al.
Publicado: (2016)

Meta-analysis of the adverse events associated with extended-release versus standard immediate-release pramipexole in Parkinson disease
por: Shen, Zhengze, et al.
Publicado: (2018)

Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real‐world claims data analysis
por: Sussman, D., et al.
Publicado: (2017)

Qualitative Analysis of Factors Influencing Patient Persistence and Adherence to Prescribed Overactive Bladder Medication in UK Primary Care
por: Ali, Mahmood, et al.
Publicado: (2019)

Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain
por: Pergolizzi, Joseph, et al.
Publicado: (2018)

Immediate switching from a chrono to an extended-release formulation of divalproex sodium: A two-part study in patients with controlled epilepsy
por: Shukla, Rakesh, et al.
Publicado: (2008)

Overactive bladder
por: Wallace, Karen M., et al.
Publicado: (2015)

Cystinosis: Therapy adherence and metabolic monitoring in patients treated with immediate-release cysteamine
por: Linden, Simone, et al.
Publicado: (2020)

Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review
por: Yeowell, Gillian, et al.
Publicado: (2018)

Pharmacokinetics of Coadministration of Guanfacine Extended Release and Methylphenidate Extended Release
por: Roesch, Benno, et al.
Publicado: (2013)

Switching From Immediate-Release to Delayed-Release Prednisone in Moderate to Severe Rheumatoid Arthritis: A Practice-Based Clinical Study
por: Dikranian, Ara H., et al.
Publicado: (2017)

Adherence to Overactive Bladder Syndrome Treatments Recent Developments and Future Perspectives
por: Robinson, Dudley, et al.
Publicado: (2023)

Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers
por: Yoon, Seonghae, et al.
Publicado: (2014)

Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes
por: Derosa, Giuseppe, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_63i1k916udarejgvgasv3mt68q